Management of Chronic Kidney Disease with GFR 30 ml/min/1.73 m²

Initial Evaluation and Monitoring

The American Society of Nephrology recommends comprehensive laboratory monitoring every 3 months for patients with GFR 30 ml/min/1.73 m², including complete anemia workup, mineral-bone disorder assessment, cardiovascular risk evaluation, and preparation for potential renal replacement therapy 1, 2, 3
A patient with GFR 30 ml/min/1.73 m² requires immediate nephrology referral, as indicated by the American Society of Nephrology 1, 2, 3
The National Kidney Foundation suggests checking hemoglobin and complete anemia workup including iron studies if hemoglobin is <12 g/dl in women or <13 g/dl in men 1, 2
Anemia evaluation is critical at this GFR threshold as erythropoietin deficiency becomes prevalent, according to the American Society of Nephrology 1, 2

The American Society of Nephrology recommends measuring serum calcium, phosphorus, and intact parathyroid hormone (iPTH) at baseline 1, 2, 3
Check 25(OH) vitamin D levels if iPTH >100 pg/ml (or >1.5 times upper limit of normal), as suggested by the National Kidney Foundation 1, 2, 3

Obtain complete lipid panel including triglycerides, LDL, HDL, and total cholesterol, as recommended by the American Heart Association 1, 2, 3, 4
Evaluate for secondary causes of dyslipidemia including comorbid conditions and medications, according to the American Society of Nephrology 2, 4

Check blood pressure at every clinic visit, minimum every 3 months, as recommended by the American Heart Association 1, 2, 3, 4
Target blood pressure <130/80 mmHg, according to the American Society of Nephrology 2, 3, 4

Immediate referral to nephrology services is mandatory at GFR <30 ml/min/1.73 m², as indicated by the American Society of Nephrology 3
Begin discussions about renal replacement therapy modalities (hemodialysis, peritoneal dialysis, transplantation), according to the National Kidney Foundation 2, 3, 4

The American Journal of Kidney Diseases states that patients with Stage 4 CKD (GFR 15-29 mL/min/1.73 m²) have a high prevalence of bone disease, with rising PTH levels and falling vitamin D levels as GFR declines below 60 mL/min/1.73 m² 5, 6, 7, 8

The radiotracer used in standard bone scans does not accumulate dangerously in renal failure and can be performed without dose modification, according to the American Journal of Kidney Diseases 9
The American Journal of Kidney Diseases recommends that the small amount of radiation exposure from bone scans is not contraindicated by kidney disease 5

The Kidney International guideline recommends performing DEXA scans to assess fracture risk in patients with CKD Stage 4 and evidence of CKD-MBD, with multiple prospective studies documenting that lower DEXA BMD predicts incident fractures in patients with CKD G3a-G5D 10
Patients with GFR 6-26 mL/min/1.73 m² (Stage 4) have the lowest BMD levels at spine, hip, and distal forearm, according to the American Journal of Kidney Diseases 7, 8, 11

A bone biopsy should be considered if knowledge of the type of renal osteodystrophy will impact treatment decisions, according to the Kidney International guideline, with specific indications including fractures with minimal or no trauma, intact PTH levels between 100-500 pg/mL with unexplained hypercalcemia, severe bone pain, or unexplained increases in bone alkaline phosphatase, suspected aluminum bone disease, and before initiating bisphosphonate therapy in patients with CKD-MBD 6, 10

Standard bone radiographs are NOT indicated for assessment of bone disease in CKD, with only 60% sensitivity and 75% specificity for detecting osteitis fibrosa, according to the American Journal of Kidney Diseases 6, 9

The American Journal of Kidney Diseases recommends measuring serum calcium, phosphorus, and intact PTH every 3 months in patients with CKD Stage 4 6